# EnPlusOne Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/enplusone-biosciences

- Industry: Biotechnology
- Headquarters: Watertown, US
- Website: www.enplusonebio.com
- Total disclosed funding: $22M
- Latest round: Seed (Dec 26, 2024)
- Investors on record: 3

## About

Founded in 2022 by Daniel Wiegand (CEO), and Jonathan Rittichier
 (CSO), and based in Massachusetts, US, EnPlusOne Biosciences Inc. was formed as a technology spinout from the Wyss Institute for Biologically Inspired Engineering at Harvard University and operates as a biotechnology research company that develops an ezRNa platform, used for RNA synthesis. In September 2022, EnPlusOne Biosciences Inc. raised USD 12 million in seed funding led by Northpond Ventures, with participation from Breakout Labs, and Coatue Management.

The company provides a patented ezRNA technology that incorporates a diverse array of nucleotide modifications for enzymatically building RNA as well as offers long-term manufacturing solutions to sustainably deliver RNA medicines at scale. The technology offers site-specific and diverse RNA alterations to aid in the commercialization of RNA oligonucleotides used in a variety of medicines.

The company intends to use the September 2022 funding to enhance its product offerings.

## Funding rounds

- Seed, Dec 26, 2024, $9.9M — Breakout Ventures, Northpond Ventures
- Seed, Aug 30, 2022, $12M — Coatue Management, Breakout Ventures, Northpond Ventures

## Investors

- Coatue Management (https://capitalatlas.ai/funds/coatue-management) — Seed
- Breakout Ventures (https://capitalatlas.ai/funds/breakout-ventures) — Seed
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Seed